IRCT20200105046010N87招募中Unknown
Bioequivalence study of Abirateron 500mg tablet (Bratiga) manufactured by Abidi Co versus originator brand (Zytiga 500) manufactured by Janssen biotech Co. in Iranian healthy volunteers
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Abirateron
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Abiraterone tablet 500 mg Actero Middle East with brand drug (ZYTIGA® 500 mg, Janssen Biotech, Germany)Bio equivalence test.IRCT20200105046010N57Actero middle east Pharm Co.24
招募中
不适用
In-vivo Bioequivalence Test of Abiraterone tablets with brand drug (ZYTIGA® 500 mg, Janssen Biotech, Germany)Bio equivalence test.IRCT20200105046010N55anoalvand Pharmaceutical Co24
招募中
不适用
In-vivo Bioequivalence Test of Abiraterone tablet 250 mg Sobhan Oncology with brand drug (ZYTIGA® 500 mg, Janssen Biotech, Germany)IRCT20200105046010N59Sobhan Oncology Pharmaceutical CO.24
已完成
2 期
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)NCT04862091Jiangsu HengRui Medicine Co., Ltd.69
尚未招募
不适用
The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer.castration resistant prostate cancerJPRN-UMIN000027795Department od Urology, Yamaguchi Graduate School of Medicine20